Patents Represented by Attorney, Agent or Law Firm Robert P. Blackburn
  • Patent number: 6521225
    Abstract: The present invention is directed to a recombinant adenovirus vector comprising two inverted terminal repeats (ITRs) each of which comprises a D-sequence having (i) from 5 to 15 native nucleotides and (ii) one or more deletions or substitutions therein.
    Type: Grant
    Filed: September 2, 1997
    Date of Patent: February 18, 2003
    Assignees: Chiron Corporation, Advanced Research and Technology Institute
    Inventors: Arun Srivastava, Selvarangan Ponnazhagan, Robert H. Chloemer, Xu-Shan Wang, Mervin C. Yoder, Shang-Zhen Zhou, Jaime Escobedo, Varavani Dwarki
  • Patent number: 6514731
    Abstract: Human hepatitis C virus (HCV) has been identified as the aetiological agent of non-A, non-B hepatitis (NANBH). HCV viruses display considerable genotypic and phenotypic heterogeneity. Thus, there is considerable need in the art for more sensitive reagents that facilitate the detection of HCV variants. The genome of hepatitis C virus (HCV) consists of seven functional regions: the core, E1, E2/NS1, NS2, NS3, NS4, and NS5 regions. An attempt was made to improve the sensitivity of anti-HCV assays by developing multiple copy epitope fusion antigens (MEFAs) which incorporate the major immunodominant epitopes from the functional regions of the HCV genome. These MEFAs are encompassed by the following generic structural formula: (A)x—(B)y—(C)z. This formula represents a linear amino acid sequence comprising multiple copies of one HCV epitope (A) linked to multiple copies of another HCV epitope (B) which in turn is linked to multiple copies of yet another HCV epitope (C).
    Type: Grant
    Filed: May 24, 1996
    Date of Patent: February 4, 2003
    Assignee: Chiron Corporation
    Inventors: Pablo D. T. Valenzuela, David Ying Chien
  • Patent number: 6512102
    Abstract: The invention is generally directed to compositions and methods for affecting signal transduction using the casein kinase I (CKI) gene or gene product. The invention is more specifically directed to affecting the Wnt signal pathway using the CKI gene or gene product. The invention is particularly directed to using the CKI gene or gene product to treat and diagnose cancer, particularly breast and colon cancer. CKI&egr; is the preferred species. The field of the invention is compositions and methods for modulating signal transduction using the (CKI) gene or gene products and variants thereof. The invention is more specifically directed to modulating the Wnt signal pathway using the CKI gene or gene product. The invention is particularly directed to using the CKI gene or gene product to treat and diagnose disorders mediated by the Wnt signal pathway, especially hyperproliferative disorders, particularly breast and colon cancer.
    Type: Grant
    Filed: December 23, 1999
    Date of Patent: January 28, 2003
    Assignee: Chiron Corporation
    Inventors: Licen Xu, Stephen D. Harrison, Lewis T. Williams
  • Patent number: 6500635
    Abstract: A purified insulin-like growth factor binding protein (IGFBP) selected from the group consisting of insulin-like growth factor binding protein having an amino acid sequence that, preferably, is at least 70% homologous to the amino acid sequence of FIG. 1 and fragments thereof that are capable of binding to an antibody specific for the protein or to an insulin-like growth factor is described. This new IGFBP is designated herein as IGFBP-5. Recombinant DNA molecules encoding the binding proteins and subsequences thereof are also described along, with recombinant microorganisms and cell lines containing the DNA molecules and methods for producing the binding proteins using recombinant hosts containing the relevant DNA molecules. Antibodies to the protein, useful in various diagnostic applications, are also described.
    Type: Grant
    Filed: November 28, 1994
    Date of Patent: December 31, 2002
    Assignee: Chiron Corporation
    Inventor: Michael C. Kiefer
  • Patent number: 6495349
    Abstract: Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 17, 2002
    Inventors: Harry E. Gruber, Douglas J. Jolly, James G. Respess, Paul K. Laikind
  • Patent number: 6492112
    Abstract: A human gene encoding a novel mitogen-activated (MAP) kinase kinase, MKK7, provides methods and reagents for treating a variety of MKK7-mediated disorders, such as ischemic heart disease, kidney failure, oxidative liver damage, respiratory distress syndrome, heat and radiation burns, septic shock, autoimmune disorders, and inflammatory diseases. MKK7 reagents can also be used to induce or prevent apoptosis.
    Type: Grant
    Filed: December 7, 1998
    Date of Patent: December 10, 2002
    Assignee: Chiron Corporation
    Inventors: Christoph Reinhard, Altaf Kassam, David Pot
  • Patent number: 6489137
    Abstract: Methods are provided for assessing mutations and/or loss of the huBUB1 gene in human tumors. Loss of wild-type huBUB1 genes is involved in neoplastic development. Therapeutic regimens can be planned on the basis of the mutational status of huBUB1.
    Type: Grant
    Filed: June 11, 1998
    Date of Patent: December 3, 2002
    Assignee: Chiron Corporation
    Inventor: Todd W. Seeley
  • Patent number: 6489294
    Abstract: Purified C-terminally truncated insulin-like growth factor binding protein-5 (IGFBP-5) compounds are described. The compounds are mitogenic and bind to insulin-like growth factors (IGFs) with decreased affinity. The C-terminally truncated IGFBPs can be produced recombinantly.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 3, 2002
    Assignees: Chiron Corporation
    Inventors: Dennis L. Andress, Michael C. Kiefer
  • Patent number: 6489344
    Abstract: New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: December 3, 2002
    Assignee: Chiron Corporation
    Inventors: John M. Nuss, Stephen D. Harrison, David B. Ring, Rustum S. Boyce, Sean P. Brown, Dane A. Goff, Kirk W. Johnson, Keith B. Pfister, Savithri Ramurthy, Paul A. Renhowe, Lynn Seely, Sharadha Subramanian, Allan S. Wagman, Xiaohui A. Zhou
  • Patent number: 6476207
    Abstract: This invention relates to novel human genes, to proteins expressed by the genes, and to variants of the proteins. The invention also relates to diagnostic and therapeutic agents related to the genes and proteins, including probes, antisense constructs, and antibodies. The invention further relates to polynucleotides differentially expressed in prostate cancer.
    Type: Grant
    Filed: June 9, 1999
    Date of Patent: November 5, 2002
    Assignee: Chiron Corporation
    Inventors: Jimmy Zhang, Jon H. Astle, Eddie Carroll, III, Wilson O. Endege, Donna M. Ford, John E. Monahan, Robert Schlegel, Kathleen E. Steinmann
  • Patent number: 6472180
    Abstract: The Hepatitis C Virus (HCV) NS3 protein contains amino acid motifs of a serine proteinase, a nucleotide triphosphatase (NTPase), and an RNA helicase. A carboxy fragment of the HCV NS3 protein was purified and possessed RNA helicase activity. Detections from the amino terminus resulted in the protein becoming soluble. Deletions from the carboxy terminus do not result in a loss of helicase activity until at least 50 amino acids are deleted. The helicase activity requires ATP and divalent cations such as Mg2+ and Mn2+. The helicase activity was blocked by monoclonal antibody specific to the HCV NS3 protein.
    Type: Grant
    Filed: January 15, 2000
    Date of Patent: October 29, 2002
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, Jang Han, Joonho Choe
  • Patent number: 6468790
    Abstract: Gene sequences as shown in SEQ ID NOS:1-85 have been found to be significantly associated with metastatic potential of cancer cells, especially breast and colon cancer cells. Methods are provided for determining the risk of metastasis of a tumor, which involve determining whether a tissue sample from a tumor expresses a polypeptide encoded by a gene as shown in SEQ ID NOS:1-85, or a substantial portion thereof.
    Type: Grant
    Filed: November 13, 2000
    Date of Patent: October 22, 2002
    Assignee: Chiron Corporation
    Inventor: Klaus Giese
  • Patent number: 6468986
    Abstract: This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.
    Type: Grant
    Filed: July 21, 2000
    Date of Patent: October 22, 2002
    Assignee: Chiron Corporation
    Inventors: Ronald N. Zuckermann, Nathalie Dubois-Stringfellow, Varavani Dwarki, Michael A. Innis, John E. Murphy, Fred E. Cohen, Tetsuo Uno
  • Patent number: 6465634
    Abstract: Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: October 15, 2002
    Assignees: Chiron Corporation, Washington University
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, Barbara A. Belli, Sondra Schlesinger, Sergey A. Dryga, Ilya Frolov
  • Patent number: 6465231
    Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3&agr; and GSK3&bgr; polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: October 15, 2002
    Assignee: Chiron Corporation
    Inventors: Stephen D. Harrison, John A. Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y. Fang, Doris G. Coit, Steve H. Nguyen, Angelica Medina-Selby
  • Patent number: 6458370
    Abstract: Compositions are provided which include biodegradable microparticles with entrapped or adsorbed antigens, in combination with submicron oil-in-water emulsions. Also provided are methods of immunization which comprise administering to a vertebrate subject (a) a submicron oil-in-water emulsion, and (b) a therapeutically effective amount of a selected antigen entrapped in a microparticle.
    Type: Grant
    Filed: August 20, 2001
    Date of Patent: October 1, 2002
    Assignee: Chiron Corporation
    Inventors: Derek O'Hagan, Gary Van Nest, Gary S. Ott, Manmohan Singh
  • Patent number: 6458527
    Abstract: Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.
    Type: Grant
    Filed: June 28, 1993
    Date of Patent: October 1, 2002
    Assignee: Chiron Corporation
    Inventors: Paul A. Luciw, Dino Dina, Kathelyn Steimer, Ray Sanchez Pescador, Carlos George-Nascimento, Deborah Parkes, Rob Hallewell, Philip J. Barr, Martha Truett
  • Patent number: 6458560
    Abstract: Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: October 1, 2002
    Assignees: Chiron Corporation, Washington University
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, Barbara A. Belli, Sondra Schlesinger, Sergey A. Dryga, Ilva Frolov
  • Patent number: 6455298
    Abstract: Animal cells are described which can be infected by influenza viruses and which are adapted to growth in suspension in serum-free medium. Processes for the replication of influenza viruses in cell culture using these cells are furthermore described, as well as vaccines which contain the influenza viruses obtainable by the process or constituents thereof.
    Type: Grant
    Filed: September 29, 1998
    Date of Patent: September 24, 2002
    Assignee: Chiron Behring GmbH & Co.
    Inventors: Albrecht Gröner, Jürgen Vorlop
  • Patent number: 6451592
    Abstract: Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.
    Type: Grant
    Filed: October 6, 1997
    Date of Patent: September 17, 2002
    Assignees: Chiron Corporation, Washington University
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, Barbara A. Belli, Sondra Schlesinger, Sergey A. Dryga, Ilya Frolov